

Editorial

Noninvasive Ultrasound in Oncologic Follow Up of Head and Neck Cancer?

Bozzato A¹ and Künzel J²¹University Hospital Homburg/Saar, Department of Otorhinolaryngology, Germany²University Hospital Mainz, Department of Otorhinolaryngology, Germany

***Corresponding author:** Alessandro Bozzato Senior Registrar, Deputy Head of Department, University Hospital Saarland, Department of Otorhinolaryngology, Germany

Received: November 20, 2017; **Accepted:** December 13, 2017; **Published:** December 21, 2017

Editorial

In Head and Neck Squamous Cell Carcinoma (HNSCC) there are no evidence-based international staging or restaging guidelines. Decisions concerning whether to perform surgery or to follow a non surgical regime are often a result in the respective tumor conferences and are therefore subject to variance. Recommendations are given on the basis of results endoscopy and imaging findings. The modality of imaging (CT, MRI, PET Scan or ultrasound (US) necessary however remains controversial.

Depending on TNM stage and anatomic site surgical and non surgical options are available [1].

In approximately 40% of cases the patients present with limited or early-stage cancer and these cases are usually treated with surgery or radiation alone. For most patients with locally advanced disease surgery combined with adjuvant therapy or chemoradiation as curative treatment options are discussed individually in interdisciplinary tumor boards [2,3,4].

However, concurrent Chemoradiotherapy (CRT) is increasingly applied as the definitive treatment of choice for locoregional advanced HNSCC with improved clinical outcome [5]. The question arises if post-radiation neck dissection should be performed routinely because available imaging modalities do not reliably identify residual disease [6], or if clinicians are able to measure treatment response of regional lymph node disease to select patients for salvage neck dissection with residual neck disease and to identify patients suitable for clinical follow-up and close observation [7,8].

PET scan is in some countries the imaging tool of “first choice” in oncologic staging superceding the role of CT and MRI scanning [9]. The main argument is that it provides a complete staging procedure and may reduce neck dissections [9-11]. Nevertheless PET scan is expensive and not readily available in many countries. Undisputed is the prognostic impact of local and regional tumor control as numerous studies confirmed [12-15]. So what imaging may be recommended?

In literature and in the US guidelines of the NCCN (National Comprehensive Cancer Network) lymph nodes of the neck may be

Table 1: US Diagnostic criteria in the differentiation of benign and malignant nodes of the neck.

	Benign	Malignant
Form	Oval	Round
Boundary	Sharp	blurred
Hilar sign	hyperechoic hilum	no hilum
Vessels	hilarvascularization	tangential vascularisation
Dynamic behaviour	Stationary	increase of size
Intranodale necrosis	Keine	anechoic central region in heterogeneous lymph node texture

evaluated by palpation, US, CT and/or MRI apart from PET scan. [16-19].

In some parts of Europe, high-resolution US and color duplex ultrasound is a well-established and proven method in the context of oncologic follow up after primary therapy of head and neck cancer.

High-resolution US (B-mode and color-duplex) clearly detect morphological parameters indicating malignant transformation of neck lymph nodes or offers evaluation of tumor extend of the pharyngeal and laryngeal area. Another essential aspect in sonographic and noninvasive follow-up is the accurate and standardized documentation (DICOM, PACS) of findings and to control dynamic changes during follow-up performed by the physician who does endoscopic exam in these patients. Sonographic imaging resolution reaches the submillimetre level, further features as elastography and contrast agents (CEUS) enhance diagnostic impact [20-25].

Limits in detection of metastatic lymph nodes are shared equally by US, CT, MRI and PET scan, when a lesion is of size smaller than 3mm. [26-37]. Table 1 main criteria to evaluate and differentiate enlarged neck lymph nodes [26-34]. The small number of studies comparing US, CT and MRI confirm the value of US in oncologic lymph node evaluation in oncologic follow [38-46] some even propagate US as method of choice [47-59] and corroborate our own experiences.

References

- Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. *Mayo Clin Proc.* 2008; 83: 489-501.
- Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. *Mayo Clin Proc.* 2016; 91: 386-396.
- Barkley HT, Fletcher GH, Jesse RH, Lindberg RD. Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx. *Am J Surg.* 1972; 124: 462-467.
- Mendenhall WM, Million RR, Cassisi NJ. Squamous cell carcinoma of the head and neck treated with radiation therapy: the role of neck dissection for clinically positive neck nodes. *Int J Radiat Oncol Biol Phys.* 1986; 12: 733-740.

5. Ong SC, Schöder H, Lee NY, Patel SG, Carlson D, Fury M, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemo radiotherapy for Loco regional advanced head and neck cancer. *J Nucl Med*. 2008; 49: 532-540.
6. Frank DK, Hu KS, Culliney BE, Persky MS, Nussbaum M, Schantz SP et al. Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer. *Laryngoscope*. 2005; 115: 1015-1020.
7. Mau T, Oh Y, Bucci MK, Eisele DW. Management of cervical metastases in advanced squamous cell carcinoma of the tonsillar fossa following radiotherapy. *Arch Otolaryngol Head Neck Surg*. 2005; 131: 600-604.
8. Hermann RM, Christiansen H, Rodel RM., Lymph node positive head and neck carcinoma after curative radiochemotherapy: a long lasting debate on elective post-therapeutic neck dissections comes to a conclusion. *Cancer Radiother*. 2013; 17: 323-331.
9. Ichimiya Y, Alluri K, Marcus C, Best S, Chung CH, Subramaniam RM, et al. Imaging modality utilization trends in patients with stage III-IV oropharyngeal squamous cell carcinoma. *Am J Nucl Med Mol Imaging*. 2015; 5: 1541-1561.
10. Hamoir M, Ferlito A, Schmitz S, Hanin FX, Thariat J, Weynand B, et al. The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. *Oral Oncol*. 2012; 48: 203-210.
11. Mehanna H, Wai-Lup Wong, Christopher C, McConkey, Joy Rahman, Max Robinson, Andrew G J, et al. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. *N Engl J Med*. 2016; 374: 1444-1454.
12. Leibel SA, Scott CB, Mohiuddin M, Marcial VA, Coia LR, Davis LW, et al. The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. *Int J Radiat Oncol Biol Phys*. 1991; 21: 549-556.
13. Brizel DM, Prosnitz RG, Hunter S, Fisher SR, Clough RL, Downey MA, et al., Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. *Int J Radiat Oncol Biol Phys*. 2004; 58: 1418-1423.
14. Lavertu P, Adelstein DJ, Saxton JP, Secic M, Wanamaker JR, Eliachar I, et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. *Head Neck*. 1997; 19: 559-566.
15. Steinkamp HJ, Cornehl M, Hosten N, Pegios W, Vogl T, Felix R. et al. Cervical lymphadenopathy: ratio of long- to short-axis diameter as a predictor of malignancy. *Br J Radiol*. 1995; 68: 266-270.
16. Cannady S B, Lee W T, Scharpf J, Lorenz R R, Wood B G, Strome M, et al. Extent of neck dissection required after concurrent chemoradiation for stage IV head and neck squamous cell carcinoma. *Head Neck*. 2010; 32: 348-356.
17. Ian Ganly, Jennifer Bocker, Diane Carlson, Salvatore Arpa, Maria Coleman, Nancy Lee, et al. Viable tumor in post chemoradiation neck dissection specimens as an indicator of poor outcome. *Head Neck*. 2011; 33: 1387-1393.
18. Williams G O, Gonzalez A I, Künzel S, Lozano M, Oliva E, Iwan B, et al. Fourier transform holography with high harmonic spectra for attosecond imaging applications. *Opt Lett*. 2015; 40: 3205-3208.
19. Kutler D I, Patel S G, Shah J P. The role of neck dissection following definitive chemoradiation. *Oncology (Williston Park)*. 2004; 18: 993-998.
20. Bozzato A, Loika A, Hornung J, Koch M, Zenk J, Uter W, et al. Comparison of conventional B-scan, tissue harmonic imaging, compound imaging and tissue harmonic compound imaging in neck lesion characterisation. *Eur Arch Otorhinolaryngol*. 2010; 267: 1593-1598.
21. Mantsopoulos K, Klintworth N, Iro H, Bozzato A. Applicability of shear wave elastography of the major salivary glands: values in healthy patients and effects of gender, smoking and pre-compression. *Ultrasound Med Biol*. 2015; 41: 2310-2318.
22. Klintworth N, Mantsopoulos K, Zenk J, Psychogios G, Iro H, Bozzato A. et al., Sonoelastography of parotid gland tumours: initial experience and identification of characteristic patterns. *Eur Radiol*. 2012; 22: 947-956.
23. Poanta L, Serban O, Pascu I, Pop S, Cosgarea M, Fodor D, et al. The place of CEUS in distinguishing benign from malignant cervical lymph nodes: a prospective study. *Med Ultrason*. 2014; 16: 7-14.
24. Slaisova R, Benda K, Jarkovsky J, Petrasova H, Szturz P, Valek V, et al. Contrast-enhanced ultrasonography compared to gray-scale and power doppler in the diagnosis of peripheral lymphadenopathy. *Eur J Radiol*. 2013; 82: 693-698.
25. Strieth S, Siedek V, Rytvina M, Gürkov R, Berghaus A, Clevert D A, et al. Dynamic contrast-enhanced ultrasound for differential diagnosis of submandibular gland disease. *Eur Arch Otorhinolaryngol*. 2014; 271: 163-169.
26. Furukawa MK, Furukawa M, Diagnosis of lymph node metastases of head and neck cancer and evaluation of effects of chemoradiotherapy using ultrasonography. *Int J Clin Oncol*. 2010; 15: 23-32.
27. Ying M, Ahuja A, Brook F, Brown B, Metreweli C. Sonographic appearance and distribution of normal cervical lymph nodes in a Chinese population. *J Ultrasound Med*. 1996; 15: 431-436.
28. Rubaltelli L, Proto E, Salmasso R, Bortoletto P, Candiani F, Cagol P, et al. Sonography of abnormal lymph nodes in vitro: correlation of sonographic and histologic findings. *AJR Am J Roentgenol*. 1990; 155: 1241-1244.
29. Alam F, Naito K, Horiguchi J, Fukuda H, Tachikake T, Ito K, et al. Accuracy of sonographic elastography in the differential diagnosis of enlarged cervical lymph nodes: comparison with conventional B-mode sonography. *AJR Am J Roentgenol*. 2008; 19: 604-610.
30. Ying M, Bhatia KS, Lee YP, Yuen HY, Ahuja AT. Review of ultrasonography of malignant neck nodes: greyscale, Doppler, contrast enhancement and elastography. *Cancer Imaging*. 2013; 13: 658-669.
31. Bruneton JN, Roux P, Caramella E, Demard F, Vallicioni J, Chauvel P. Ear, nose, and throat cancer: ultrasound diagnosis of metastasis to cervical lymph nodes. *Radiology*. 1984; 152: 771-773.
32. Tschammler A, Ott G, Schang T, Seelbach-Goebel B, Schwager K, Hahn D, et al. Lymphadenopathy: differentiation of benign from malignant disease-color Doppler US assessment of intranodal angioarchitecture. *Radiology*. 1998; 208: 117-123.
33. Na DG, Lim HK, Byun HS, Kim HD, Ko YH, Baek JH, et al. Differential diagnosis of cervical lymphadenopathy: usefulness of color Doppler sonography. *AJR Am J Roentgenol*. 1997; 168: 1311-1316.
34. Wu CH, Chang YL, Hsu WC, Ko JY, Sheen TS, Hsieh FJ, et al. Usefulness of Doppler spectral analysis and power Doppler sonography in the differentiation of cervical lymphadenopathies. *AJR Am J Roentgenol*. 1998; 171: 503-509.
35. Choi YJ, Lee JH, Baek JH. Ultrasound elastography for evaluation of cervical lymph nodes. *Ultrasonography*. 2015; 34: 157-164.
36. Desmots F, Fakhry N, Mancini J, Reyre A, Vidal V, Jacquier A, et al. Shear Wave Elastography in Head and Neck Lymph Node Assessment: Image Quality and Diagnostic Impact Compared with B-Mode and Doppler Ultrasonography. *Ultrasound Med Biol*. 2016; 42: 387-398.
37. King AD, Tse GM, Ahuja AT, Yuen EH, Vlantis AC, To EW et al. Necrosis in metastatic neck nodes: diagnostic accuracy of CT, MR imaging, and US. *Radiology*. 2004; 230: 720-726.
38. Fleischman GM, Thorp BD, Difurio M, Hackman TG. Accuracy of Ultrasonography-Guided Fine-Needle Aspiration in Detecting Persistent Nodal Disease After Chemoradiotherapy. *JAMA Otolaryngol Head Neck Surg*. 2016; 142: 377-382.
39. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009; 45: 228-247.
40. Hoang JK, Vanka J, Ludwig BJ, Glastonbury CM. Evaluation of cervical lymph nodes in head and neck cancer with CT and MRI: tips, traps, and a systematic approach. *AJR Am J Roentgenol*. 2013; 200: 17-25.
41. Yoon DY, Hwang HS, Chang SK, Rho YS, Ahn HY, Kim JH, et al. CT, MR,

- US, 18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. *Eur Radiol*. 2009; 19: 634-642.
42. Schouten CS, de Graaf P, Alberts FM, Hoekstra OS, Comans EF, Bloemena E, et al. Response evaluation after chemoradiotherapy for advanced nodal disease in head and neck cancer using diffusion-weighted MRI and 18F-FDG-PET-CT. *Oral Oncol*. 2015; 51: 541-547.
43. Schouten CS. Response evaluation after chemoradiotherapy for advanced staged oropharyngeal squamous cell carcinoma: a nationwide survey in the Netherlands. *Eur Arch Otorhinolaryngol*. 2015; 272: 3507-3513.
44. Pellini R., Manciocco V, Turri-Zanoni M, Vidiri A, Sanguineti G, Marucci L, et al. Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease. *J Craniomaxillofac Surg*. 2014; 42: 1834-1839.
45. Hong SF. Efficiency of three-dimensional Doppler ultrasonography in assessing nodal metastasis of head and neck cancer. *Eur Arch Otorhinolaryngol*. 2015; 272: 2985-2991.
46. Nishimura G, Yabuki K, Hata M, Komatsu M, Taguchi T, Takahashi M, et al. Imaging strategy for response evaluation to chemoradiotherapy of the nodal disease in patients with head and neck squamous cell carcinoma. *Int J Clin Oncol*. 2016; 21: 658-667.
47. de Bondt R.B, Nelemans PJ, Hofman PA, Casselman JW, Kremer B, van Engelshoven JM, et al., Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging. *Eur J Radiol*. 2007; 64: 266-272.
48. Peng C, Liu LZ, Zheng W, Xie YJ, Xiong YH, Li AH, et al. Can quantitative contrast-enhanced ultrasonography predict cervical tumor response to neoadjuvant chemotherapy? *Eur J Radiol*. 2016; 85: 2111-2118.
49. Gatidis S, Graf H, Weiß J, Stemmer A, Kiefer B, Nikolaou K, et al. Diffusion-weighted echo planar MR imaging of the neck at 3 T using integrated shimming: comparison of MR sequence techniques for reducing artifacts caused by magnetic-field inhomogeneities. *MAGMA*. 2017; 30: 57-63.
50. Lerant G, Sarkozy P, Takacs-Nagy Z, Polony G, Tamas L, Toth E, et al. Dynamic Contrast-Enhanced MRI Parameters as Biomarkers in Assessing Head and Neck Lesions After Chemoradiotherapy Using a Wide-Bore 3 Tesla Scanner. *Pathol Oncol Res*. 2015; 21: 1091-1099.
51. Min SJ, Jang HJ, Kim JH, Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review. *Oncotarget*. 2016; 7: 27848-27854.
52. Robbins KT. Effectiveness of superselective and selective neck dissection for advanced nodal metastases after chemoradiation. *Arch Otolaryngol Head Neck Surg*. 2005; 131: 965-969.
53. Suarez C, Rodrigo JP, Robbins KT, Paleri V, Silver CE, Rinaldo A, et al. Superselective neck dissection: rationale, indications, and results. *Eur Arch Otorhinolaryngol*. 2013; 270: 2815-2821.
54. Kwong DL, Nicholls J, Wei WI, Chua DT, Sham JS, Yuen PW, et al. The time course of histologic remission after treatment of patients with nasopharyngeal carcinoma. *Cancer*. 1999; 85: 1446-1453.
55. Shah K, Te Marvelde L, Collins M, De Abreu Lourenco R, D'Costa I, Coleman A, et al. Safety and cost analysis of an (18)FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation. *Oral Oncol*. 2015; 51: 529-535.
56. Pryor DI. Economic analysis of FDG-PET-guided management of the neck after primary chemoradiotherapy for node-positive head and neck squamous cell carcinoma. *Head Neck*. 2013; 35: 1287-1294.
57. Nishimura G, Komatsu M, Hata M, Yabuki K, Taguchi T, Takahashi M, et al. Predictive markers, including total lesion glycolysis, for the response of lymph node(s) metastasis from head and neck squamous cell carcinoma treated by chemoradiotherapy. *Int J Clin Oncol*. 2016; 21: 224-230.
58. Bar-Ad V. Positron emission tomography for neck evaluation following definitive treatment with chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma. *Rev Recent Clin Trials*. 2012; 7: 36-41.
59. McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, et al. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. *Head Neck*. 2004; 26: 890-896.